Analysis of 3,760 hematologic malignancies reveals rare transcriptomic aberrations of driver genes

Xueqi Cao[1,2], Sandra Huber[3], Ata Jadid Ahari[1], Franziska R. Traube[1,4], Marc Seifert[5], Christopher C. Oakes[6], Polina Secheyko[1,7], Sergey Vilov[8], Ines Scheller[1,8], Nils Wagner[1,9], Vicente A. Yépez[1], Piers Blombery[10,11,12], Torsten Haferlach[3], Matthias Heinig[1,8], Leonhard Wachutka[1]*, Stephan Hutter[3]*, Julien Gagneur[1,2,8,13]*

[1] School of Computation, Information and Technology, Technical University of Munich, Garching, Germany

[2] Graduate School of Quantitative Biosciences (QBM), Munich, Germany

[3] Münchner Leukämielabor GmbH (MLL), Munich, Germany

[4] Institute of Biochemistry and Technical Biochemistry, University of Stuttgart, Stuttgart, Germany

[5] Department of Haematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany

[6] Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA

[7] Faculty of Biology, Ludwig-Maximilians-University Munich, Munich, Germany

[8] Computational Health Center, Helmholtz Center Munich, Neuherberg, Germany

[9] Helmholtz Association - Munich School for Data Science (MUDS), Munich, Germany

[10] Peter MacCallum Cancer Centre, Melbourne, Australia

[11] University of Melbourne, Melbourne, Australia

[12] Torsten Haferlach Leukaemiediagnostik Stiftung, Munich, Germany

[13] Institute of Human Genetics, School of Medicine, Technical University of Munich, Munich, Germany

* Corresponding authors

Julien Gagneur: gagneur@in.tum.de

Stephan Hutter: stephan.hutter@mll.com

Leonhard Wachutka: wachutka@cit.tum.de

Abstract

Background

Rare oncogenic driver events, particularly affecting the expression or splicing of driver genes, are suspected to substantially contribute to the large heterogeneity of hematologic malignancies. However, their identification remains challenging.

Methods

To address this issue, we generated the largest dataset to date of matched whole genome sequencing and total RNA sequencing of hematologic malignancies from 3,760 patients spanning 24 disease entities. Taking advantage of our dataset size, we focused on discovering rare regulatory aberrations. Therefore, we called expression and splicing outliers using an extension of the workflow DROP (Detection of RNA Outliers Pipeline) and AbSplice, a variant effect predictor that identifies genetic variants causing aberrant splicing. We next trained a machine learning model integrating these results to prioritize new candidate disease-specific driver genes.

Results

We found a median of seven expression outlier genes, two splicing outlier genes, and two rare splice-affecting variants per sample. Each category showed significant enrichment for already well-characterized driver genes, with odds ratios exceeding three among genes called in more than five samples. On held-out data, our integrative modeling significantly outperformed modeling based solely on genomic data and revealed promising novel candidate driver genes. Remarkably, we found a truncated form of the low density lipoprotein receptor *LRP1B* transcript to be aberrantly overexpressed in about half of hairy cell leukemia variant (HCL-V) samples and, to a lesser extent, in closely related B-cell neoplasms. This observation, which was confirmed in an independent cohort, suggests *LRP1B* as a novel marker for a HCL-V subclass and a yet unreported functional role of *LRP1B* within these rare entities.

Conclusions

Altogether, our census of expression and splicing outliers for 24 hematologic malignancy entities and the companion computational workflow constitute unique resources to deepen our understanding of rare oncogenic events in hematologic cancers.

Keywords

Aberrant Expression, Aberrant Splicing, *LRP1B*, Hairy Cell Leukemia Variant (HCL-V), Driver Gene Prediction

Background

Hematologic malignancies are characterized by abnormal blood cells in the bone marrow, peripheral blood, or lymphatic organs. They can occur in various forms, affecting the myeloid or lymphoid cell lineage. In 2020, hematologic malignancies accounted for approximately 2.5% of new cancer cases globally and accounted for 3.1% of cancer-associated mortality (1). While some subtypes, like myeloproliferative neoplasm, exhibit a high degree of uniformity in their manifestation and genetic profile, others, like myelodysplastic neoplasm, display a significantly broader spectrum, hampering correct diagnosis and therapy decisions and negatively impacting treatment outcomes and survival (2). Thus, better understanding the variety of oncogenic events for each disease entity is of utmost interest to refine diagnostics and facilitate the development of new therapeutic options.

Within the last decade, the identification of driver genes in hematologic malignancies has been dramatically enhanced by the utilization of next-generation sequencing. This has provided valuable insights into the underlying genetic landscape of each entity and triggered a revision of the classification systems, which now emphasize genomics-based categorization of various leukemia and lymphoma entities (2–5). However, despite significant progress in understanding recurrent driver mutations in hematologic malignancies, much remains to be learned about the rare events within each disease entity that drive their individual development and progression (6,7).

Alterations of gene expression and splicing play a key role in cancer (8), particularly in hematologic malignancy pathogenesis (9–19). For instance, many hematologic malignancies are characterized by altered expression resulting from gene rearrangements that lead to the overexpression of specific transcription factors or cell cycle regulators. Examples include acute myeloid leukemia (AML) with defining genetic alterations (20), *BCR::ABL1*-positive chronic myeloid leukemia (CML) (21), or *CCND1* rearrangements in mantle cell lymphoma (MCL) (2,22). Moreover, aberrant splicing can generate gain or loss-of-function transcript isoforms of driver genes for many cancer types (23). For example, multiple aberrant splice isoforms of the *TP53* transcript have been observed in CML, even in the absence of genomic mutations around exon-intron junctions (24). However, a systematic analysis of rare expression and splicing aberrations among hematologic malignancies is still lacking.

To address this gap, we conducted a comprehensive analysis of genomes (Whole Genome Sequencing, WGS) and matched transcriptomes (total RNA sequencing, RNA-Seq) of tumor tissues from 3,760 patients spanning 24 hematologic malignancy entities (Figure 1). We analyzed this data using RNA-seq-based expression and splicing outlier callers, as well as AbSplice, a tool we recently published that predicts rare genetic variants causing aberrant splicing. We demonstrate how these results can be utilized to identify a novel marker for a rare entity and enhance the prediction of hematologic malignancy driver genes beyond the commonly used mutational recurrence. In summary, our study aims to deepen our understanding of the role of rare gene expression and RNA splicing in the development of hematologic malignancies and provide novel driver gene candidates.

Methods

Dataset

Patients

We used genomic and transcriptomic data from the Munich Leukemia Laboratory (MLL). We included a total of 3,760 tumor samples sent to the MLL between September 2005 and April 2019 for routine diagnostic workup (Table 1). Diagnoses from peripheral blood or bone marrow were based on cytomorphology, immunophenotype, cytogenetics, and molecular genetics, as previously described (25–27). All patients or their legal guardians gave written informed consent for genetic analyses and to the use of laboratory results and clinical data for research purposes, according to the Declaration of Helsinki. The study was approved by the MLL's institutional review board. The dataset spanned 24 disease entities (Table 1).

Table 1. Disease entities enrolled and corresponding study groups

Disease entity	**Abbreviation**	**Number of samples per disease entity**	**Study group**	**Number of samples per study group**
Acute myeloid leukemia	AML	730	AML	730
Myelodysplastic neoplasm	MDS	713	MDS	713
Marginal zone lymphoma	MZL	71	MatureB group	375
Mantle cell lymphoma	MCL	71		
High-grade B-cell lymphoma	HGBL	61		
Lymphoplasmacytic lymphoma	LPL	59		
Follicular lymphoma	FL	57		

Other B-cell non-Hodgkin lymphomas	B-NHL	56		
Myeloproliferative neoplasm	MPN	344	MPN	344
Chronic lymphocytic leukemia	CLL	279	CLL	279
Multiple myeloma	MM	236	PCN group	247
Monoclonal gammopathy of undetermined significance	MGUS	11		
Myelodysplastic/myeloproliferative neoplasm, unclassifiable	MDS/MPN-U	81	MDS/MPN group	207
Atypical chronic myeloid leukemia	aCML	67		
Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis	MDS/MPN-RS-T	59		
B-cell precursor acute lymphoblastic leukemia	BCP-ALL	204	BCP-ALL	204
T-cell non-Hodgkin lymphoma	T-NHL	90	T-cell group	174
T-cell acute lymphoblastic leukemia	T-ALL	84		
Chronic myelomonocytic leukemia	CMML	142	CMML	142
Mastocytosis		98	Mastocytosis	98
Hairy cell leukemia	HCL	68	Hairy-cell group	97
Hairy cell leukemia variant	HCL-V	29		
Chronic myeloid leukemia	CML	92	CML	92
Chronic lymphoproliferative disorder of natural killer cells	CLPD-NK	58	NK	58

Sample preparation

DNA and total RNA from peripheral blood and bone marrow samples were extracted using the MagNA Pure 96 Instrument and the MagNAPure96 DNA and Viral NA LV Kit and MagNA Pure

96 Cellular RNA LV Kit, respectively (Roche LifeScience, Mannheim, Germany). WGS and RNA-seq were performed on the prepared samples (Supplementary Materials and Methods).

Variant calling and annotation

Variant calling of single nucleotide variants, short insertions and deletions, structural variants, copy number variations, and gene fusions were performed on all samples as described previously (28–31) (Supplementary Materials and Methods). The analysis was based on the GENCODE v33 (32) annotation and using the reference genome GRCh37.

As matched germline tissues for the tumor samples were unavailable, sex-matched genomic DNA from random healthy donors was used as normal material during tumor-normal variant calling. To reduce germline variants and artifacts from the data, we filtered single nucleotide variants, short insertions, and deletions with the following criteria:

1) Only consider variants emitted with “PASS” quality
2) Discard variants with gnomAD v2.1.1 (33) minor allele frequency > 0.05%
3) Discard variants with sample variant allele frequency < 0.1

To reduce germline variants and artifacts from structural variant calls we only considered variants meeting the following criteria:

1) Only consider variants emitted with “PASS” quality
2) Only consider variants if they have three or more paired-reads supporting it
3) Discard variants found with exact breakpoint locations in the gnomAD SV database (34)
4) Discard variants that are found in four or more different myeloid and four or more different lymphatic entities

To predict the effects of variants on splicing, we applied AbSplice-DNA v1.0.0 (35) to the filtered variants. AbSplice-DNA estimates the probability that a rare variant causes aberrant splicing in a given tissue, which takes the variant and splice annotations, so-called SpliceMaps, as input.

We generated SpliceMaps for each study group as described previously (35). The variants with an AbSplice-DNA prediction score ≥ 0.2 were classified as splice-affecting variants. Further variant effect predictions were obtained by applying Ensembl VEP v81 (36). VEP splice-related variants were defined as VEP calculated consequences ‘splice_acceptor_variant’ (2 base region at the 3' end of an intron), ‘splice_donor_variant’ (2 base region at the 5' end of an intron), and ‘splice_region_variant’ (1-3 bases of the exon or 3-8 bases of the intron).

Gene-level mutational recurrence scores were obtained using IntOGen commit 437a047 (37), and MutSigCV v1.41 (38). To this end, the variants were additionally filtered using the following criteria:

1) Discard variants with sample variant allele frequency < 0.15 as this more stringent cutoff led to improved driver gene enrichments

2) Only consider variants with VEP calculated impact ‘HIGH’, ‘MODERATE’, ‘LOW’ or calculated consequence '5_prime_UTR_variant', '3_prime_UTR_variant', and 'coding_sequence_variant'

3) Only consider variants supported by at least 20 reads

Expression and splicing outlier calling

We implemented a python backend version of OUTRIDER v.1.99.0 (39) for scalability (see Availability of data and materials) and applied it to RNA-seq data using DROP v1.1.0 (40) w(40)default settings to call expression outliers at a False Discovery Rate (FDR) of 0.05. Expression outliers with lower-than-average expressions (z-score < 0) were defined as underexpression outliers, and higher-than-average expressions (z-score > 0) as overexpression outliers.

FRASER v.1.99.0 (41) was applied to RNA-seq data using DROP v1.2.3 (40) with default settings to call splicing outliers (FDR < 0.05). We grouped the samples into 14 study groups

based on hematopoietic cell origins and pathologies (2–5) to ensure sufficient sample sizes (Table 1, N at least 58). Splicing outliers with delta Intron Jaccard Index >0 were defined as overrepresented splicing outliers, and delta Intron Jaccard Index <0 as underrepresented splicing outliers.

As OUTRIDER is restricted to commonly-expressed genes defined as genes with fragments per kilobase of transcript per million mapped reads (FPKM) larger than 1 in at least 5% of the samples, we introduced a novel method to detect aberrant activation of genes usually not expressed. This method, NB-act (Negative Binomial activation), provides *P*-values for observed fragment count (read pairs) for each gene in each sample under the null hypothesis that the gene is not expressed in the sample. Specifically, NB-act computes the probability of observing a certain number of fragments or more for a gene in a particular sample, assuming a negative binomial distribution with an expected baseline expression of 1 FPKM and a dispersion parameter of 0.02 (Supplementary Materials and Methods). The FPKM value of 1 corresponds to the threshold separating expressed from non-expressed genes in OUTRIDER (39). The dispersion parameter of 0.02 corresponds to the empirically observed lowest dispersion values estimated by OUTRIDER on expressed genes. As low dispersion corresponds to high variance, we chose a low dispersion value for NB-act to be conservative. NB-act was applied to rarely-expressed genes (FPKM>1 in at least one sample but less than 5% of the samples).

Enrichment for driver gene and variant categories

The enrichment of cancer driver genes was evaluated by the Fisher test using Cancer Gene Census (CGC) GRCh37 v97 (42) (Supplementary Materials and Methods). The role of hematologic malignancy driver genes was determined using annotation ‘Tissue Type’ and ‘Role in Cancer’.

As promoter variants, we considered all single nucleotide variants and short insertions and deletions less than 2,000 bp away from the transcription start site of the corresponding gene. Frameshift and stop gained variants were detected with Ensembl VEP v81. The enrichment analysis of variants within expression outlier gene-sample pairs was performed using the Fisher test. Sample-gene pairs with other variants were excluded apart from those for which enrichment was calculated.

Survival analysis

Overall survival analyses were performed according to Kaplan-Meier and compared using two-sided log-rank tests with the statistical software R v4.2.2 with the survival (43) and survminer (44) packages. The overall survival was calculated as the time from diagnosis to death or last follow-up.

Driver gene prediction

Machine-learning models were trained to predict the probability of a gene to be a hematologic malignancy driver gene. To this end, random forest classifiers (Python package scikit-learn v1.0.2) (45) were trained to predict driver genes using gene-level features obtained from all samples on the one hand and each of the 14 study groups on the other hand. The gene-level features consisted of 21 features from seven gene-level metrics of seven intOGen tools, nine features from AbSplice-DNA scores, 22 features from OUTRIDER obtained using combinations of fold-change direction, significance, and effect size cutoffs, and, similarly, 11 features from NB-act and 22 features from FRASER (Supplementary Materials and Methods). In total, 377 genes listed among the hematologic panel genes (Supplementary Materials and Methods) or the hematologic malignancy driver genes from CGC GRCh37 v97 were used as the positive class for the classifiers. The random forests were trained using the function ‘RandomForestClassifier’ with the minimum of number of samples required to split an internal

nodes set to 19, the maximal tree depth set to 10, and default settings otherwise (Supplementary Materials and Methods). The models were trained with 5-fold cross-validation, stratified to preserve the percentage of positive class in all folds, using the function 'StratifiedKFold' from the Python package scikit-learn v1.0.2. Performances were evaluated by precision-recall curves on the held-out data. Subsequently, only prediction values on held-out data were used for candidate curation. As the predicted probabilities range very differently across study groups, no fixed threshold was set, and we focused on the rank of the predicted genes. The benchmark against intOGen and MutSigCV was conducted on all study groups.

Further detailed descriptions are available in the Supplementary Materials and Methods.

Validation HCL-V dataset

Patients

The validation HCL-V dataset included a total of 42 patients, including 14 HCL-V and 28 HCL patients. The HCL-V patients were diagnosed based on immunophenotype and morphological characteristics consistent with HCL-V, including all CD5 negative, CD11c positive, and CD123 negative markers. All HCL-V patients were confirmed as *BRAF*-V600E negative.

Sample preparation

Tumor cells were isolated by cell sorting (purity > 99%) as $FSC^{high}CD20^{+}CD11c^{+}$ and kappa/lambda light chain restriction. RNA was isolated by the RNeasy Micro Kit (Qiagen, Hilden, Germany).

RNA sequencing, read mapping

For the generation of RNA-sequencing libraries, the NuGEN Trio RNA-Seq System (NuGEN, Redwood City, California) was used. Samples were split equally and processed in independent sequencing steps to allow for the correction of batch effects. Sequencing was performed with paired-end sequencing and two times 100-bp length. Sequences were aligned with HiSAT2 v2.1.0 (46) to the GRCh38.

Gene expression analysis

Gene expression was analyzed with DESeq2 (47). The size factor was calculated using DEseq2. The counts were normalized by size factors. The activation of *LRP1B* was determined with a two-component Gaussian mixture clustering with equal variance on size factor-normalized and log-transformed counts, using the R package 'mclust' v.6.0.0 (48).

Results

We investigated WGS and RNA-seq data from 3,760 tumor samples representing 24 different types of leukemia and lymphoma (Table 1). This is the largest collection of hematologic malignancy samples with WGS and matched RNA-seq, which also includes rare disease entities like hairy cell leukemia variant (HCL-V) and chronic lymphoproliferative disorder of natural killer cells. In order to restrict our analysis to putative rare germline and somatic variants, we filtered variants called on WGS with stringent quality filters and population allele frequency (33). We next annotated the genes using the seven features from the software intOGen, which include positional recurrence of mutations in genome sequence (OncodriveCLUSTL), positional recurrence of mutations in protein conformation (HotMAPS), enrichment of mutations in functional domains (smRegions), three alternative measures of selection strength inferred from synonymous and nonsynonymous mutations (CBaSE, MutPanning, and dNdScv), and

OncodriveFML, a method identifying excess of somatic mutations across tumors in both coding and non-coding genomic regions (37,49–55). Moreover, we annotated genetic variants falling into gene bodies, including deep intronic variants, with AbSplice-DNA, a tool predicting variants causing aberrant splicing (35). On the RNA-seq data, we used OUTRIDER on a total of 12,966 protein-coding genes commonly expressed across the dataset to call high or low expression outliers, and FRASER to call splicing outliers (39,41). We also introduced a new method, NB-act, to call rare aberrant activation of genes mainly not expressed (Methods). Combining all these results, we established a unique census of genomic and transcriptomic aberrations in 3,760 hematologic malignancy samples (Figure 1).



Figure 1. Overview of the study. Dataset: Whole genome sequencing and total RNA sequencing of 3,760 hematologic malignancies spanning 24 different disease entities. Bioinformatic processing: On genomic data, intOGen captures recurrent mutational patterns (37), and AbSplice predicts variants causing aberrant splicing (35). Working on RNA-seq data, OUTRIDER calls expression outliers of commonly expressed genes (39), NB-act calls

overexpression of rarely expressed genes (Methods), and FRASER calls splicing outliers (41). Census: a unique collection of genomic and transcriptomic aberrations for 24 hematologic malignancy entities. Downstream analysis: driver gene prediction and enrichment analysis per disease entity.

Expression outliers are enriched for hematologic malignancy driver genes

Case-control differential expression analysis identifies common differences between tumor and healthy samples and, therefore, can be suited to identify recurrently differentially expressed genes in tumors. To identify potential rare driver genes, we instead employed expression outlier analysis, which calls rare, aberrantly high, or low expression of a gene within a dataset. OUTRIDER calls expression outliers by modeling read count distribution across samples and reporting the statistical significance of extreme observations. Moreover, OUTRIDER controls for gene expression covariations, which allows automatic corrections for technical sources of variation, such as batch effects, and adjusts for transcriptome-wide co-regulation patterns due to trans-acting regulatory changes. Deviations from these variations have been shown to be enriched for rare variants with strong cis-regulatory effects (39) and help identify causes of rare disorders (56–59). Applying OUTRIDER, we called 21,264 underexpression outliers (median of 2 per sample) and 14,041 overexpression outliers (median of 2 per sample) on 10,193 different protein-coding genes (Supplementary Figures 1-2). To verify whether these outliers are associated with cancer, we calculated their enrichment for reported hematologic malignancy driver genes, which we adapted from CGC (42). We observed a strong enrichment for CGC hematologic tumor suppressor genes among underexpression outliers and for CGC hematologic oncogenes among overexpression outliers (Figure 2A-B). Notably, the genes called as outliers in more than five samples exhibited the highest enrichment, indicating that genes frequently called as outliers are more likely to be oncogenic. Moreover, we found that the number of expression outliers per sample was unevenly distributed (Supplementary Figures 1-2). Samples with numerous outliers may either represent cases where OUTRIDER could not adequately fit

the data or situations where the gene regulatory network is globally affected, resulting in widespread expression aberrations throughout the genome. We reasoned that the enrichment for driver genes among expression outliers could be lower in all those samples. Indeed, the enrichment for tumor suppressor genes and oncogenes increased when focusing on the three most significant outliers (at most three) in each sample (Figure 2A-B).


A
Underexpression outliers (OUTRIDER)
At most three
All
n =
5.4k 9.4k 3.1k 2.2k 3.2k 1.1k 1.2k 238
Enrichment for hematologic tumor supressor genes (Odds ratio)
Samples per gene
B
Overexpression outliers (OUTRIDER)
n =
5.8k 8.7k 3.7k 2.9k 3k 1.2k 411 118
Enrichment for hematologic oncogenes (Odds ratio)
C
Activation outliers (NB-act)
n =
4.4k 5.3k 608 334 491 232 524 179
D
TET2
Outlier
Non-outlier
Raw counts + 1
Expected counts + 1
T-ALL_0269
AML_0405
E
AML_0405
Gene expression z-score
UBE2D3
TET2
Genomic position on chromosome 4 (MB)
F
T-ALL_0269
FAM241A
PDGFC
NFKB1
G
Copy ratio
H

Figure 2. Expression outliers are enriched for hematologic malignancy driver genes. (A) Enrichment for CGC hematologic tumor suppressor genes among all genes called by OUTRIDER as well as at most three significant genes per sample that were called to be underexpression outliers. The genes are stratified by the number of samples in which the gene is called as an outlier. Numbers of the genes and nominal significances from the Fisher test are labeled at the top of the bars (ns: not significant; *: $P \leq 0.05$; **: $P \leq 0.01$; ***: $P \leq 0.001$; ****: $P \leq 0.0001$). **(B-C)** As in A) for CGC hematologic oncogenes among overexpression and activation outliers, respectively. **(D)** Raw RNA-seq read counts per sample against expected counts for *TET2*. For fifteen samples (red), *TET2* was called as an underexpression outlier, including samples AML_0405 and T-ALL_0269, showcased in the panels (E-H). **(E-F)** Gene expression z-score among all samples against the genomic position of the genes on chromosome 4. **(G-H)** Copy ratio within chromosome 4 binned into one-kb region. Red vertical lines mark the genomic position of the expression outliers. Black dashed lines mark the estimated region of no copy number variation. The underexpression outliers in *TET2* and *UBE2D3* in sample AML_0405 reflect the consequence of copy number loss that is very specific to the *TET2* locus. In contrast, an extra copy of whole chromosome 4 (karyotype: 47,XY,+4) is found in sample T-ALL_0269. *TET2* reduced expression must have a different cause in this sample.

OUTRIDER filters out genes expressed in less than 5% of samples due to statistical modeling limitations, leaving a gap in detecting rare gene activation. To fill this gap, we developed a complementary algorithm, NB-act (Methods). We applied it to the 6,017 rarely-expressed protein-coding genes filtered out by OUTRIDER. NB-act identified 10,263 activation outliers among 1,623 genes (with a median of 0 and 75% quantile of 2 per sample, Supplementary Figure 3). We observed a notable enrichment for CGC hematologic oncogenes among all activation outliers (Figure 2C). Here too, restricting to at most three outliers per sample increased the enrichment. Altogether, these analyses provide a unique set of aberrantly expressed genes in hematologic malignancies with strong enrichment for driver genes.

We next investigated how expression outliers were associated with genomic alterations. We observed a strong enrichment of relevant genomic aberrations among the expression outliers. Overall, 18.8% of the underexpression outliers could be explained by a copy number loss, and

11.4 % of the overexpression outliers and 10.2% of the activation outliers could be explained by a copy number gain (Supplementary Figure 4). We also found significant enrichments for rare variants associated with nonsense-mediated decay (stop-gained, frameshift, and splice-related) as well as structural variants and variants found in the promoter region among underexpression outliers (Methods, Supplementary Figure 5), consistent with earlier reports in non-cancer samples (60). Structural variants were also significantly enriched among overexpression and activation outliers (Supplementary Figure 6-7). Interestingly, we found enrichments for rare splice-related variants and rare frameshift variants among overexpression outliers but not activation outliers, perhaps because, in some cases, these variants lead to RNAs with increased stability (Supplementary Figure 6-7). Overall, these enrichments for relevant genomic aberrations support the reliability of the expression outlier calls and provide a genetic explanation for a substantial fraction of them.

Investigations of expression outlier events of the tumor suppressor gene *TET2* illustrate how this catalog can be used. Loss of function of *TET2* has been reported in myeloid leukemia due to splice site mutations, out-of-frame insertions or deletions, and base substitutions (61–64). We found 15 underexpression outlier events (two in AML, one in myelodysplastic neoplasm, seven in B-cell precursor acute lymphoblastic leukemia, and five in T-cell acute lymphoblastic leukemia) for *TET2* across all samples and no overexpression outliers (Figure 2D), consistent with its role as a tumor suppressor gene. To gain further insights, we showcased the two samples with the lowest fold changes (samples AML_0405 and T-ALL_0269). For these two samples, *TET2* was among the most extreme outliers (Supplementary Figure 8-9). However, neither the single nucleotide variants, short insertions and deletions, structural variants, nor gene fusions explained the observed decrease in *TET2* expression. Inspection of the genomic coverage indicated a loss of the *TET2* locus nested within a single-copy loss of a larger region in chromosome 4 for sample AML_0405. This explanation was further supported by the

decreased expression of the neighbor gene *UBE2D3* (Figure 2 E, G). In contrast, genomic coverage investigations did not provide an explanation for the reduced expression of *TET2* in sample T-ALL_0269. Further outliers, including *TET2* in sample T-ALL_0269, could reflect yet-to-be-interpreted genetic variants, epigenetic causes, or outlier caller false positives (65).

In summary, both OUTRIDER and NB-act reveal aberrantly expressed genes enriched for driver genes and can be used to identify downregulated tumor suppressor genes or activated oncogenes in individual samples.

Rare splicing aberrations are enriched for hematologic malignancy driver genes

We applied FRASER to detect aberrant splicing events (aberrant usage of existing or novel splice sites) within our samples, which could be caused by events such as alternative exon usage, intron retention, alternative donor or acceptor site usage, usage of deep intronic donor and acceptor sites or truncation of parts of the transcript. Like OUTRIDER for expression, FRASER is a tool to call splicing outliers while controlling for covariations, a task that is distinct from calling differential splicing between groups (41). We called 43,464 splicing outliers across 35,410 gene-level splicing outlier events on a total of 7,591 genes in 2,854 samples (Supplementary Figure 10). Remarkably, we observed a substantial enrichment for CGC hematologic tumor suppressor genes among these splicing outliers (Figure 3A). As for expression outliers, restricting to at most three outliers per sample increased the enrichment. Moreover, the genes called as splicing outliers in more than five samples exhibited the highest enrichment, suggesting a higher potential of being oncogenic.

Calling splicing aberrations from RNA-seq data can point toward mutations that have been overlooked using the genomic data alone. As an example, we showcase RB1, a well-known tumor suppressor gene, which can be inactivated by various mechanisms, including intragenic

mutations, methylation of the promoter region, and chromosomal deletions (66). In sample B-NHL_1747, we identified an unusual exon-skipping event of the 20th exon in RB1 (Supplementary Figure 11). Analyzing the WGS data of this sample revealed a deletion of 118-base-pair in the region of the 20th exon, which led to a frame-shift exon-skipping (Supplementary Figure 12). However, this structural variant was initially discarded in our variant calling pipeline due to stringent filtering. Using FRASER, which accurately captured the consequence of this initially discarded structural variant as a splicing outlier, we were now able to recognize its significant transcriptomic impact and rescue it.


A
Called splicing outliers (FRASER)
At most three
All
n =
9.8k
15.4k
2.2k
1.7k
3.6k
890
2.7k
260
ns
ns
Enrichment for hematologic tumor supressor genes (Odds ratio)
Samples per gene
0
1
2-4
≥5
B
Predicted splice-affecting variants (AbSplice)
16.6k
16.9k
2.1k
2k
1.1k
939
228
191
C
Splice-affecting variants (AbSplice)
Splicing outliers (FRASER)
Splice-related variants (VEP)
1293
91
35190
958
4747
546
116505
D
Overlap of splicing outliers (FRASER) and splice-affecting variants (AbSplice)
19.3k
19.4k
570
567
148
148
18
18
E
Intron chr19: 42,384,806-42,384,933, CD79A
Outlier
Non-outlier
LPL_0664
MZL_3758
Junction counts + 1
Total junction coverage + 2
F
NM_001783.4:c.568-2_610del
MZL_3758 (Case)
LPL_0664 (Case)
MCL_1229 (Control)
42
964
126
62
2
11
2274
42384751
42384843
42384937
42385033
Genomic coordinate (chr19), "+" strand
CD79A
4
5

Figure 3. Transcriptomic splicing outliers and genomic splice-affecting variants are enriched for hematologic malignancy driver genes. (A) Enrichment for CGC hematologic tumor suppressor genes among all genes called by FRASER and at most three significant genes per sample that were called aberrantly spliced from RNA-seq (FRASER). The genes are stratified by the number of samples in which a gene is called as a splicing outlier. Numbers of the genes and their nominal significance from the Fisher test are labeled at the top of the bars. **(B)** As in (A) among splice-affecting variants (AbSplice). **(C)** Overlap of splice-affecting variants, VEP splice-related variants, and splicing outliers on the sample-gene level. **(D)** As in (A) among splice-affecting variants with corresponding splicing outliers. **(E)** Junction counts (split reads) against total junction coverage (exon-intron or intron-exon spanning reads) of the displayed intron. The displayed intron of the *CD79A* only shows aberrant splicing in samples MZL_3758 and LPL_0664. **(F)** Sashimi plots showing RNA-seq read coverage (y-axis) and the numbers of split reads spanning an intron indicated on the exon-connecting line (using pysashimi) for two aberrant splicing events. Two case samples using a unique splice-site in *CD79A* 5th exon acceptor site and one control sample are displayed. The rare splice-affecting deletion (NM_001783.4:c.568-2_610del) predicted by AbSplice, which existed exclusively in the two case samples, is shown as black bars.

As a complementary approach to RNA-seq-based splicing outlier calling, we considered AbSplice (35), a recently published algorithm that predicts whether a rare variant causes aberrant splicing. Here, we applied it for the first time to hematologic malignancy samples. AbSplice integrates two sequence-based machine learning tools, MMSplice (67) and SpliceAI (68), with so-called SpliceMaps, which are quantified tissue-specific usages of splice sites, including non-annotated and weak splice sites. We derived SpliceMaps from the raw RNA-seq data (Methods). AbSplice classified 7,160 rare variants as splice-affecting out of 275,899,978 pre-filtered variants, resulting in 7,074 genes predicted to be affected across 3,093 samples (with a median of 2 per sample, Supplementary Figure 13). These results demonstrated a strong enrichment for CGC hematologic tumor suppressor genes among all genes carrying splice-affecting variants (Figure 3B). Furthermore, when focusing on the genes that were predicted to have recurrent aberrant splicing events across multiple samples, we observed an

even higher enrichment, indicating a tendency for recurrent splice-affecting variants to occur in known hematologic malignancy driver genes (Figure 3B). In contrast to the RNA-seq-based splicing outlier calls, restricting AbSplice predictions to at most three calls per sample did not lead to a significantly higher enrichment, likely due to the limited number of samples with a high number of variants displaying strong AbSplice scores. Collectively, these results indicate that the rare splicing aberrations predicted from the genome can contribute to identifying potential driver genes in hematologic malignancies.

Overall, 15% of the AbSplice predictions (1,049 out of 7,089, Figure 3C) were also called as splicing outliers by FRASER, which is lower but not far off the claimed precision of AbSplice at the cutoff we used (predicted precision cutoff = 0.2). This proportion of FRASER splicing outliers was much larger using AbSplice than when using VEP splice-related rare variants (1.2%, 1,504 out of 121,256, Figure 3C). Among those 1,049 gene-sample pairs common to AbSplice and FRASER, the enrichment for CGC hematologic tumor suppressor genes was substantially stronger than when considering AbSplice predictions or FRASER calls separately (Figure 3D). As an example of an event both predicted by AbSplice and called by FRASER, we showcase *CD79A*, a well-known oncogene frequently affected by somatic mutations in hematologic malignancies (42,69–71). We discovered splicing outliers of *CD79A* in samples MZL_3758 and LPL_0664, resulting in a truncation of 18 amino acids at the beginning of the 5th exon (Figure 3E). AbSplice predicted that a rare 45-base-pair deletion spanning the acceptor site (NM_001783.4:c.568-2_610del) to be splice-affecting (AbSplice score = 0.36, Figure 3F, Supplementary Figure 14). This deletion, which was exclusively found in these two samples, is very likely the cause of this aberrant splicing event. Notably, similar deletions in the 4th and 5th exon of *CD79A* have been observed in diffuse large B-cell lymphoma, which has been shown to impact the ITAM signaling modules (69).

In summary, variants predicted to cause aberrant splicing by AbSplice and splicing outliers called by FRASER in transcriptomic data showed global enrichment for driver genes and proved invaluable in pinpointing affected driver genes in individual samples.

All our results from splice-affecting variants, expression outliers, splicing outliers, and recurrent mutational patterns aggregated by disease entities are provided (Availability of data and materials). This constitutes a comprehensive census detailing genomic and transcriptomic aberrations across 3,760 hematologic malignancy samples.

Integration of rare genomic and transcriptomic aberrations improves hematologic malignancy driver gene prediction

We next trained models to predict driver genes based on genomic and transcriptomic features, including the seven intOGen tools, AbSplice, OUTRIDER, NB-act, and FRASER. To this end, we used the complete dataset on the one hand and used the dataset stratified by 14 study groups on the other hand (Table 1). As ground truth, we considered the 322 CGC hematologic malignancy driver genes complemented with 55 additional curated hematologic panel genes (Methods). The performance of all 15 models was evaluated using 5-fold cross-validation (Methods).

Using the complete dataset, we found that the genomic and transcriptomic features exhibited complementary predictive value for hematologic malignancy driver genes (Figure 4A-B, Supplementary Figure 15-16). Specifically, integrating AbSplice variant effect predictions significantly enhanced the genomic-based model trained on the seven intOGen tools. Moreover, we found that the transcriptomic features further significantly improved the model (Figure 4B). These findings underscore the relevance of incorporating aberrant expression and splicing

analyses to predict driver genes. Among the 100 top-ranked genes, 63 were known from the ground truth, vastly greater than expectation (odds ratio = 106.3, $P = 1.6 \times 10^{-84}$, Fisher test; Figure 4C, Supplementary Table 1). These enrichments for well-known driver genes demonstrated the reliability of the model predictions. Four genes, *CDNKN1B*, *EIF3E*, *HLA-A,* and *IL6ST*, are CGC driver genes that have not been annotated as hematologic yet, indicating a broader role for those. Despite *TTN* being known to be false positive in mutational recurrence analysis as a long gene, the remaining genes were categorized as candidate drivers whose role remains to be further assessed.


A
Individual feature
Linear cluster of mutations (OncodriveCLUSTL)
3D cluster of mutations (HotMAPS)
Cluster in domain (smRegions)
Functional impact bias (OncodriveFML)
Excess of mutations (CBaSE)
Trinucleotide-specific bias (MutPanning)
Excess of mutations (dNdScv)
Splicing variants (AbSplice)
Expression outliers (OUTRIDER+NB-act)
Splicing outliers (FRASER)
0.0
0.1
0.2
Average Precision
Feature source
Genomic
Transcriptomic
B
Cumulative feature
Linear cluster of mutations (OncodriveCLUSTL)
+ 3D cluster of mutations (HotMAPS)
+ Cluster in domain (smRegions)
+ Functional impact bias (OncodriveFML)
+ Excess of mutations (CBaSE)
+ Trinucleotide-specific bias (MutPanning)
+ Excess of mutations (dNdScv)
+ Splicing variants (AbSplice)
+ Expression outliers (OUTRIDER+NB-act)
+ Splicing outliers (FRASER)
***
**
0.0
0.1
0.2
Average Precision
Feature source
Genomic
Transcriptomic
C
Top 100 predicted genes
Manual curation
Reported hematologic malignancy driver gene (n=63)
Reported cancer driver gene (n=4)
Candidate hematologic malignancy driver gene (n=33)
D
DNMT3A
STAG2
EZH2
TET2
ASXL1
RUNX1
NRAS
CBL
CUX1
IGSF3
CSF3R
U2AF1
VWF
PRDM9
SRSF2
SF3B1
PIGQ
SETBP1
JAK2
ZNF605
TP53
AFF3
ANKRD36
ANKRD36C
UBC
CCND3
CDKN1B
BIRC3
CXCR4
ATXN3
TNFRSF14
ARID1A
CD79B
ID3
KLF2
NOTCH2
USP9Y
SORL1
HLA-A
HLA-B
ATM
CREBBP
KMT2D
IGLL5
TTN
PHF6
NOTCH1
SUZ12
FBXW7
BCL11B
DNM2
STAT3
PTEN
JAK3
STAT5B
IKZF1
PAX5
KIT
PLCG1
GNAS
TCP1
TRAF3
DIS3
SEL1L3
BRAF
ENOSF1
PCNT
WASCH2C
FLG
SP140
MYC
MYD88
ATXN1
CHD2
FBXL12
EIF4G1
HLA-DRB5
IL6ST
SH2B3
REEP4
MEGF9
EIF3E
MS4A18
BCOR
FLT3
NF1
IDH1
FAM221A
CALHM3
CEBPA
RAD21
IDH2
PTPN11
NBPF11
BRCC3
ARAP3
ZRSR2
GATA2
CHEK2
SMG1
AML
MDS
MPN
MDS/MPN group
CMML
Mastocytosis
CML
NK
PCN group
CLL
BCP-ALL
Hairy-cell group
T-cell group
MatureB group
0.0
0.5
1.0
Predicted probability
Normalized predicted probability
1.00
0.75
0.50
0.25
Cell origin
Myeloid
Lymphoid
Gene cluster
Cluster 1
Cluster 2
Cluster 3
Cluster 4
Cluster 5
Manual curation
Reported hematologic malignancy driver gene
Reported cancer driver gene
Candidate hematologic malignancy driver gene

Figure 4. Rare genomic and transcriptomic aberrations add value to hematologic malignancy driver gene prediction on top of methods detecting mutational recurrence. (A) Individual features and the corresponding model's performances (measured by average precision) using a random forest classifier. **(B)** Order as in (A) for cumulative features. The performance constantly improved when adding additional features. Asterisks denote nominal significance from the Wilcoxon test. **(C)** Numbers of genes in each category among the top 100 predicted genes when using all features and the complete dataset. Reported hematologic malignancy driver genes are the genes listed in either CGC hematologic malignancy driver genes or hematologic panel genes. Reported cancer driver genes are the genes documented by CGC. The rest of the genes are categorized as candidate hematologic malignancy driver genes. **(D)** The heatmap shows the predicted driver gene probability per gene (rows) and study group (columns) relative to the column-wise maximum value. Myeloid and lymphoid entities clustered due to the shared hematologic malignancy driver gene profiles (bottom track). The barplot shows the predicted probabilities from the model trained on the complete dataset. Bar colors as in (C).

In line with the results on the complete dataset, our integrative model outperformed or was on par with intOGen or MutSigCV - a driver gene predictor based on mutation frequency across all study groups (Supplementary Figure 17) . The study-group-wise models allowed further insights into disease-entity specificities (Figure 4D, Supplementary Table 2). Clustering the 100 top-ranked genes according to their study-group predicted probabilities revealed various disease entity specificities. Cluster 3 consisted of genes that exhibited high predicted probabilities across all disease entities. While *TP53* is a well-known pan-cancer tumor suppressor, we acknowledge that *ANKRD36*, *ANKRD36C*, and *UBC* may warrant further scrutiny as potential artifacts in global analysis (72). Clusters 1 and 2 comprised genes that scored highly specifically in myeloid disease entities, such as *ASXL1* and *SRSF2* (4,73). Conversely, the genes in the remaining clusters were associated with specific disease entities. Notable examples include *NOTCH1, PHF6, and FBXW7,* which are well-acknowledged for their role in T-cell leukemia, as well as *BRAF*, which was exclusively predicted in the hairy-cell group, in accordance with its recognized function as a marker for HCL (4,74–76).

Among the candidate genes, we identified several promising genes whose roles in hematologic malignancies are yet to be established. Our analysis predicted *SORL1* as a candidate driver in multiple study groups, including myelodysplastic neoplasm (precursor of AML), B-cell precursor ALL, and a study group comprising T-cell non-Hodgkin lymphoma and T-cell acute lymphoblastic leukemia. Consistent with these observations, *SORL1* was found to be expressed on the leukemic cell surface and released into plasma in AML and ALL, with its level decreasing during remission (77). *EIF4G1* stood out as another interesting candidate driver in AML and lymphoid entities, supported by previous analyses suggesting that *EIF4G1* is involved in cell survival in AML as a downstream target of *MYCN*, a known oncogene in neuroblastoma (78). We also found *TCP1* to be predicted in mastocytosis and B-cell precursor-ALL, whose high expression has been associated with AML drug resistance and poor survival through the activation of *AKT/mTOR* signaling (79). A fourth exciting candidate, *ATXN1,* was predicted as a candidate driver in multiple disease entities. Its important paralog *ATXN1L* is known as a novel regulator of hematopoietic stem cell quiescence (80). Overall, our predictions based on 3,760 tumor genomes and transcriptomes reveal promising hematologic malignancy driver candidates.

Outlier clustering identifies *LRP1B* as a potential marker in HCL-V and related B-cell malignancies

In addition to our global driver gene prediction analysis, we performed a detailed investigation into each disease entity, examining its association with expression outliers, splicing outliers, and variants predicted to cause aberrant splicing. Overall, we found 2,716 significant associations between 11,273 genes and 24 disease entities (Supplementary Table 3, Benjamini-Hochberg false discovery rate < 0.05, one-sided Fisher test). Focusing on activation outliers and annotated cancer driver genes, we found 43 associations between 37 CGC cancer driver genes and 12 disease entities (Figure 5A). Some associations were already described in the literature (Supplementary Table 4). For example, we confirmed that the transcription factors *TLX1* and

TLX3 were associated with T-cell acute lymphoblastic leukemia, in line with previous reports (81,82). In addition, other studies mentioned the role of *HOXA11*, *PREX2,* and *RET* in AML (83–85). However, several associations have not yet been reported, including overexpression of *WNK2* in high-grade B-cell lymphoma, of *FAT4* in multiple myeloma, and of *LRP1B* in hairy cell leukemia (HCL), hairy cell leukemia variant (HCL-V) and marginal zone lymphoma (MZL).



Figure 5. Aberrant activation of *LRP1B* is predominant in HCL-V. (A) Disease entities (full names in Table 1) against aberrantly activated CGC genes, colored by odds ratio from Fisher test. **(B)** Percentage of *LRP1B*-activated samples in the four disease entities in which *LRP1B* activation occurred. Percentages of samples showing *LPR1B* activation (NB-act) and nominal significance from the one-sided Fisher test are labeled at the top. **(C)** Normalized counts of *LRP1B*-activated samples of the dataset with regard to the different disease entities in the validation

dataset. Percentages of samples showing *LPR1B* activation (Gaussian mixture clustering) are labeled at the top. **(D)** Transcriptomic coverage tracks showing *LRP1B* truncated isoforms of samples HCL-V_3036 and MM_0496 (dataset) and HCL-V_19_Val (validation dataset). **(E)** Anticipated domain organization of truncated and canonical *LRP1B* (adapted from Príncipe et al.(86)).

Remarkably, *LRP1B* was associated with very rare entities. *LRP1B*, or Low-Density Lipoprotein Receptor-related protein 1B, is a frequently altered gene in multiple cancer types, but its exact role remains unclear (86). In total, we found 24 samples (0.6% of all 3,760 samples) with aberrant high expression of *LRP1B*. Thereof 21 were found within HCL-V, HCL, and MZL, where *LRP1B*-activated samples made up 44.8% (HCL-V), 7.4% (HCL), and 4.2% (MZL) of each entity (Figure 5B). The other three cases with high *LRP1B* expression were found within multiple myeloma (MM). Among all *LRP1B*-activated samples, more than half of the cases (13 out of 24) were found in HCL-V patients, indicating that aberrant *LRP1B* expression might play an important role in HCL-V. *LRP1B* activation did not show a significant difference in overall survival (OS) in HCL-V patients. However, a trend towards shorter OS of patients with *LRP1B* activation was observed (median OS: 3.4 vs. 6.3 years; $P = 0.45$, two-sided log-rank test; Supplementary Figure 18). We then evaluated *LRP1B* expression in an independent validation dataset of 42 samples. Consistent with observations made on our primary dataset, we detected 10 *LRP1B*-activated samples in HCL-V (5/14; 36%) and HCL (5/28; 18%, Figure 5C) in the validation dataset. Moreover, the RNA-seq coverage for both datasets showed that samples overexpressing *LRP1B* expressed a truncated isoform in the majority (32/34; 94%) of samples (22/24 in the dataset; 10/10 in the validation dataset; Figure 5D, Supplementary Figure 19-20). The two samples expressing full-length transcripts were both multiple myeloma, whose causes are yet to be understood. In the truncated isoform cases, *LRP1B* expression started at exon 13, thus lacking the first 636 amino acids of exon 1 to 12. Three start codons located within exon 13 could enable the start of translation using the canonical open reading frame. Assuming this

transcript is translated, it yields a truncated LRP1B protein starting from the middle of the second β-propeller domain (Figure 5E). However, we could not pinpoint a genomic cause for the truncated isoform, as no single nucleotide variants, short insertions or deletions, structural variants, or gene fusions involving *LRP1B* were found to be specific to the affected samples.

Discussion

The study of rare cancer aberrations is an emerging field that greatly benefits from the growing large-scale next-generation sequencing (87,88). We have generated an extensive census of rare genomic and transcriptomic aberrations across 3,760 patients spanning 24 hematologic malignancy disease entities. This census is based on the largest collection of hematologic malignancy samples that have undergone WGS along with matched RNA-seq data, which also includes rare disease entities. We cannot share without access restrictions the exact variants, expression outliers, and splicing outliers at the sample level, as such data would compromise research participant privacy. Nevertheless, we publicly provide our census (Availability of data and materials) and have demonstrated its utility. This census comprises frequencies of genes harboring variants predicted to cause aberrant splicing, expression outliers, and splicing outliers. All these categories were significantly enriched for known hematologic malignancy driver genes, highlighting their role as putative drivers in the corresponding samples. Notably, we have reaffirmed the well-established associations between transcription factors *TLX1* and *TLX3* with T-cell acute lymphoblastic leukemia, as well as *HOXA11*, *PREX2*, and *RET* with AML. Furthermore, we built pan-leukemia and entity-specific driver gene predictors by integrating this data which successfully recovered known drivers and yielded promising novel candidates.

One of our notable findings is the identification of *LRP1B* as a potential marker for a subgroup of HCL-V and related B-cell malignancies. In our RNA-seq samples, *LRP1B* expression was rarely

detected, occurring in only approximately 1% of cases. However, it was highly expressed in some cases of MZL, HCL, and approximately 50% of HCL-V, which we confirmed in an independent dataset. These three disease entities are mature B-cell malignancies and were previously regarded as separate entities in the revised 4th edition of the WHO classification of hematolymphoid tumors, distinguished based on immunophenotypic markers and molecular genetics (89). HCL-V is typically resistant to conventional HCL therapy and does not show the HCL-specific *BRAF*-V600E mutation. However, as HCL, HCL-V, and MZL arise from malignant mature B-cells showing similar morphology, clear discrimination using conventional diagnostic techniques is often not possible. Thus, in the recently published 5th edition of WHO classification, the term “HCL-V" has been removed, recognizing that the biology of this disease is unrelated to HCL (3). Instead, these cases are now considered splenic B-cell lymphoma/leukemia with prominent nucleoli (SBLPN), which also comprises rare cases of splenic MZL and B-prolymphocytic leukemia based on similar cytomorphological features. SBLPN rather serves as a placeholder for those morphologically defined cases of B-cell lymphoma not being classifiable into biologically distinct entities based on current evidence-based knowledge. We observed a tendency for a worse prognosis for HCL-V samples expressing *LRP1B*, though a larger sample size is needed to establish a statistical significance. Overall, our results suggest a potential subcategorization of HCL-V/SBLPN based on *LRP1B* expression, whose functional implications remain to be elucidated.

LRP1B, also known as Low-Density Lipoprotein Receptor-related protein 1B, is broadly expressed in multiple normal tissues but not in blood or bone marrow (90–92). It plays a role in various biological processes such as angiogenesis, chemotaxis, proliferation, adhesion, apoptosis, endocytosis, immunity, host-virus interaction, and protein folding. Additionally, *LRP1B* is among the most frequently altered genes in human cancer overall (93–98). For tissues where *LRP1B* is normally expressed, *LRP1B* is often inactivated in cancer through several genetic and

epigenetic mechanisms, making it a putative tumor suppressor gene. Overexpression of a truncated isoform of *LRP1B* in cells that normally do not express it, as we observed here, could play a role in oncogenesis by disrupting similar biological processes. Despite the challenges posed by the enormous size of LRP1B, as highlighted in the study by Príncipe et al. (86), our findings encourage further investigations to unravel the potential role of *LRP1B* in B-cell malignancies.

Our study has limitations. Our approach is not geared towards retrieving common abnormalities and may underscore non-regulatory mutations. For example, *NPM1*, one of the most frequently mutated genes in AML (99), was not prioritized. *NPM1* was categorized as a driver gene by two intOGen tools but not by the other five. Pathogenic mutations of *NPM1* act post-translationally by affecting the cellular localization of the NPM1 protein. Not surprisingly, the transcriptome data of *NPM1* were not informative. Consequently, *NPM1* was not prioritized by our driver gene prediction model. Our dataset, which is derived from routine diagnostic sampling, does not include matched healthy controls. Therefore, the variants we considered probably include more rare somatic variants than in studies with matched control samples. Additionally, we did not include gene fusion and copy number variation calls, which are frequent causes of hematologic malignancies, into the driver gene prediction model, as we found them to have very high false positive rates during preliminary investigations. Moreover, we have purposely decided to restrict the input data of the driver gene prediction model to the sole genomic and transcriptomic data of our dataset in order to provide the community predictions unbiased by previous literature. Future work could integrate this resource as prior information on pathways or protein interaction networks or with complementary datasets to provide a refined landscape of genomic and transcriptomic aberrations driving hematologic malignancies.

Conclusions

We established a unique and comprehensive census encompassing the genomic and transcriptomic landscape of 3,760 hematologic malignancy samples, covering a wide range of disease entities. This comprehensive census can be leveraged to identify novel biomarkers, propose therapeutic decisions, and unravel the molecular underpinning of the heterogeneity of hematologic cancers.

List of abbreviations

CGC	Cancer Gene Census
LRP1B	Low-Density Lipoprotein Receptor-related protein 1B
MLL	Munich Leukemia Laboratory
NB-act	Negative Binomial activation
RNA-Seq	total RNA sequencing
VEP	Ensembl variant effect predictor
WGS	Whole Genome Sequencing

Declarations

Ethics approval and consent to participate

All patients or their legal guardians gave written informed consent for genetic analyses and to the use of laboratory results and clinical data for research purposes, according to the Declaration of Helsinki. The study was approved by the MLL's institutional review board.

Consent for publication

Not applicable.

Availability of data and materials

The census of genomic and transcriptomic aberrations of 3,760 hematologic malignancy samples spanning 24 disease entities is available at https://zenodo.org/record/8341457. A data transfer agreement must be obtained to access further data, including raw genomic and transcriptomic sequencing data, as they could compromise research participant privacy. To this end, contact St.H. (stephan.hutter@mll.com) at MLL.

All code is available at https://github.com/gagneurlab/Leukemia_outlier.

Competing interests

T.H. declares part ownership of Munich Leukemia Laboratory (MLL). Sa.H. and St.H. are employed by the MLL.

Funding

This study was supported by the German Bundesministerium für Bildung und Forschung (BMBF) supported through the VALE (Entdeckung und Vorhersage der Wirkung von genetischen Varianten durch Artifizielle Intelligenz für LEukämie Diagnose und Subtypidentifizierung) project [031L0203B to X.Q., J.G.; 031L0203C to Sa.H., St.H.; and 031L0203A to S.V., M.H.]

Authors' contributions

L.W., St.H., and J.G. designed the research; X.C., Sa.H., A.J.A., M.S., P.S., and St.H. performed the research; C.O., and St.H. collected the data; X.C., Sa.H., A.J.A., M.S., I.S., and N.W. analyzed and interpreted the data; X.C., Sa.H., and S.V. performed statistical analysis; X.C.,

and A.J.A. developed the software; M.H., L.W., St.H., and J.G. supervised the research; M.H., T.H., St.H., and J.G. acquired the funding; X.C., Sa.H., A.J.A., F.R.T., M.S., S.V., L.W., St.H., and J.G. wrote the manuscript; and all authors reviewed and agreed to the final version of the manuscript.

Acknowledgments

The authors thank everyone from the MLL 5k project involved in patient inclusion, sample collection, and sequencing data generation; everyone involved in patient inclusion, sample collection, and sequencing data generation of the HCL-V validation dataset; Stefan Loipfinger, Luise Schuller, and Kim Anh Lilian Le for their contributions to the initial work of this project; Felix Brechtmann and Christian Mertes for the enlightening discussions.

Authors' information

Correspondence: Julien Gagneur, School of Computation, Information and Technology, Technical University of Munich, Boltzmannstraße 3, 85748 Garching bei München, Germany; e-mail: gagneur@in.tum.de; and Stephan Hutter, Münchner Leukämielabor GmbH (MLL), Max-Lebsche-Platz 31, 81377 München, Germany; e-mail: stephan.hutter@mll.com; and Leonhard Wachutka, School of Computation, Information and Technology, Technical University of Munich, Boltzmannstraße 3, 85748 Garching bei München, Germany; e-mail: wachutka@cit.tum.de.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36

Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–49.

2. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1703–19.
3. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 Jul;36(7):1720–48.
4. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200–28.
5. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 Sep 15;140(11):1229–53.
6. Ostroverkhova D, Przytycka TM, Panchenko AR. Cancer driver mutations: predictions and reality. Trends Mol Med. 2023 Jul 1;29(7):554–66.
7. Nussinov R, Tsai CJ, Jang H. Why Are Some Driver Mutations Rare? Trends Pharmacol Sci. 2019 Dec;40(12):919–29.
8. Calabrese C, Davidson NR, Demircioğlu D, Fonseca NA, He Y, Kahles A, et al. Genomic basis for RNA alterations in cancer. Nature. 2020 Feb;578(7793):129–36.
9. Hautin M, Mornet C, Chauveau A, Bernard D, Corcos L, Lippert E. Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues. Cancers. 2020 Aug 7;12(8):2216.
10. Grinev VV, Barneh F, Ilyushonak IM, Nakjang S, Smink J, Van Oort A, et al. RUNX1/RUNX1T1 mediates alternative splicing and reorganises the transcriptional landscape in leukemia. Nat Commun. 2021 Jan 22;12(1):520.
11. Tanaka A, Nakano TA, Nomura M, Yamazaki H, Bewersdorf JP, Mulet-Lazaro R, et al.

Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia. Blood. 2022 Aug 25;140(8):875–88.

12. Obeng EA. Mutant SF3B1 splices a more leukemogenic EVI1. Blood. 2022 Aug 25;140(8):800–1.
13. Huber S, Haferlach T, Meggendorfer M, Hutter S, Hoermann G, Baer C, et al. SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase. Leukemia. 2022 Dec;36(12):2927–30.
14. Yang YT, Chiu YC, Kao CJ, Hou HA, Lin CC, Tsai CH, et al. The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome. Blood Cancer J. 2018 Aug 13;8(8):1–11.
15. Szelest M, Masternak M, Zając M, Chojnacki M, Skórka K, Zaleska J, et al. The role of NPM1 alternative splicing in patients with chronic lymphocytic leukemia. PLOS ONE. 2022 Oct 25;17(10):e0276674.
16. Dlamini Z, Shoba B, Hull R. Splicing machinery genomics events in acute myeloid leukaemia (AML): in search for therapeutic targets, diagnostic and prognostic biomarkers. Am J Cancer Res. 2020 Sep 1;10(9):2690–704.
17. Rivera OD, Mallory MJ, Quesnel-Vallières M, Chatrikhi R, Schultz DC, Carroll M, et al. Alternative splicing redefines landscape of commonly mutated genes in acute myeloid leukemia. Proc Natl Acad Sci. 2021 Apr 13;118(15):e2014967118.
18. Black KL, Naqvi AS, Asnani M, Hayer KE, Yang SY, Gillespie E, et al. Aberrant splicing in B-cell acute lymphoblastic leukemia. Nucleic Acids Res. 2018 Nov 30;46(21):11357–69.
19. Huber S, Haferlach T, Meggendorfer M, Hutter S, Hoermann G, Summerer I, et al. Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts. Leukemia. 2023 Feb;37(2):500–2.
20. Lewis RE, Cruse JM, Sanders CM, Webb RN, Suggs JL. Aberrant expression of T-cell markers in acute myeloid leukemia. Exp Mol Pathol. 2007 Dec 1;83(3):462–3.

21. Collins S, Coleman H, Groudine M. Expression of bcr and bcr-abl fusion transcripts in normal and leukemic cells. Mol Cell Biol. 1987 Aug;7(8):2870–6.
22. Rimokh R, Berger F, Bastard C, Klein B, French M, Archimbaud E, et al. Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle- cell lymphomas and t(11q13)-associated leukemias. Blood. 1994 Jun 15;83(12):3689–96.
23. Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene. 2016 May;35(19):2413–27.
24. Nakai H, Kaneko H, Horiike S, Ariyama Y, Misawa S, Kashima K, et al. Multiple aberrant splicing of the p53 transcript without genomic mutations around exon-intron junctions in a case of chronic myelogenous leukaemia in blast crisis: a possible novel mechanism of p53 inactivation. Br J Haematol. 1994 Aug;87(4):839–42.
25. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004 Nov 15;104(10):3078–85.
26. Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, et al. Morphologic Dysplasia in De Novo Acute Myeloid Leukemia (AML) Is Related to Unfavorable Cytogenetics but Has No Independent Prognostic Relevance Under the Conditions of Intensive Induction Therapy: Results of a Multiparameter Analysis From the German AML Cooperative Group Studies. J Clin Oncol. 2003 Jan 15;21(2):256–65.
27. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002 Jan;16(1):53–9.
28. Haferlach C, Walter W, Stengel A, Meggendorfer M, Hutter S, Kern W, et al. The diverse

landscape of fusion transcripts in 25 different hematological entities. Leuk Lymphoma. 2021 Nov 10;62(13):3292–5.

29. Hershberger CE, Moyer DC, Adema V, Kerr CM, Walter W, Hutter S, et al. Complex landscape of alternative splicing in myeloid neoplasms. Leukemia. 2021 Apr;35(4):1108–20.
30. Stengel A, Baer C, Walter W, Meggendorfer M, Kern W, Haferlach T, et al. Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. Blood Adv. 2021 Nov 2;5(21):4426–34.
31. Höllein A, Twardziok SO, Walter W, Hutter S, Baer C, Hernandez-Sanchez JM, et al. The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time? Cancer Genet. 2020 Apr;242:15–24.
32. Frankish A, Diekhans M, Ferreira AM, Johnson R, Jungreis I, Loveland J, et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 2019 Jan 8;47(D1):D766–73.
33. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020 May;581(7809):434–43.
34. Collins RL, Brand H, Karczewski KJ, Zhao X, Alföldi J, Francioli LC, et al. A structural variation reference for medical and population genetics. Nature. 2020 May;581(7809):444–51.
35. Wagner N, Çelik MH, Hölzlwimmer FR, Mertes C, Prokisch H, Yépez VA, et al. Aberrant splicing prediction across human tissues. Nat Genet. 2023 May 4;1–10.
36. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016 Jun 6;17(1):122.
37. Martínez-Jiménez F, Muiños F, Sentís I, Deu-Pons J, Reyes-Salazar I, Arnedo-Pac C, et al. A compendium of mutational cancer driver genes. Nat Rev Cancer. 2020 Oct;20(10):555–72.

38. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul;499(7457):214–8.
39. Brechtmann F, Mertes C, Matusevičiūtė A, Yépez VA, Avsec Ž, Herzog M, et al. OUTRIDER: A Statistical Method for Detecting Aberrantly Expressed Genes in RNA Sequencing Data. Am J Hum Genet. 2018 Dec 6;103(6):907–17.
40. Yépez VA, Mertes C, Müller MF, Klaproth-Andrade D, Wachutka L, Frésard L, et al. Detection of aberrant gene expression events in RNA sequencing data. Nat Protoc. 2021 Feb;16(2):1276–96.
41. Scheller IF, Lutz K, Mertes C, Yépez VA, Gagneur J. Improved detection of aberrant splicing using the Intron Jaccard Index [Internet]. medRxiv; 2023 [cited 2023 May 9]. p. 2023.03.31.23287997. Available from: https://www.medrxiv.org/content/10.1101/2023.03.31.23287997v1
42. Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018 Nov;18(11):696–705.
43. Therneau TM. A Package for Survival Analysis in R [Internet]. 2023. Available from: https://CRAN.R-project.org/package=survival
44. Kassambara A, Kosinski M, Biecek P. survminer: Drawing Survival Curves using “ggplot2” [Internet]. 2021. Available from: https://CRAN.R-project.org/package=survminer
45. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: Machine Learning in Python. J Mach Learn Res. 2011;12(85):2825–30.
46. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015 Apr;12(4):357–60.
47. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014 Dec 5;15(12):550.

48. Scrucca L, Fop M, Murphy TB, Raftery AE. mclust 5: Clustering, Classification and Density Estimation Using Gaussian Finite Mixture Models. R J. 2016 Aug;8(1):289–317.
49. Arnedo-Pac C, Mularoni L, Muiños F, Gonzalez-Perez A, Lopez-Bigas N. OncodriveCLUSTL: a sequence-based clustering method to identify cancer drivers. Bioinformatics. 2019 Nov 1;35(22):4788–90.
50. Mularoni L, Sabarinathan R, Deu-Pons J, Gonzalez-Perez A, López-Bigas N. OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations. Genome Biol. 2016 Jun 16;17(1):128.
51. Tokheim C, Bhattacharya R, Niknafs N, Gygax DM, Kim R, Ryan M, et al. Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure. Cancer Res. 2016 Jul 1;76(13):3719–31.
52. Martínez-Jiménez F, Muiños F, López-Arribillaga E, Lopez-Bigas N, Gonzalez-Perez A. Systematic analysis of alterations in the ubiquitin proteolysis system reveals its contribution to driver mutations in cancer. Nat Cancer. 2020 Jan;1(1):122–35.
53. Weghorn D, Sunyaev S. Bayesian inference of negative and positive selection in human cancers. Nat Genet. 2017 Dec;49(12):1785–8.
54. Dietlein F, Weghorn D, Taylor-Weiner A, Richters A, Reardon B, Liu D, et al. Identification of cancer driver genes based on nucleotide context. Nat Genet. 2020 Feb;52(2):208–18.
55. Martincorena I, Raine KM, Gerstung M, Dawson KJ, Haase K, Van Loo P, et al. Universal Patterns of Selection in Cancer and Somatic Tissues. Cell. 2017 Nov 16;171(5):1029-1041.e21.
56. Dekker J, Schot R, Bongaerts M, de Valk WG, van Veghel-Plandsoen MM, Monfils K, et al. Web-accessible application for identifying pathogenic transcripts with RNA-seq: Increased sensitivity in diagnosis of neurodevelopmental disorders. Am J Hum Genet. 2023 Feb 2;110(2):251–72.
57. Lunke S, Bouffler SE, Patel CV, Sandaradura SA, Wilson M, Pinner J, et al. Integrated

multi-omics for rapid rare disease diagnosis on a national scale. Nat Med. 2023 Jul;29(7):1681–91.

58. Lee M, Kwong AKY, Chui MMC, Chau JFT, Mak CCY, Au SLK, et al. Diagnostic potential of the amniotic fluid cells transcriptome in deciphering mendelian disease: a proof-of-concept. NPJ Genomic Med. 2022 Dec 28;7:74.
59. Vialle RA, de Paiva Lopes K, Bennett DA, Crary JF, Raj T. Integrating whole-genome sequencing with multi-omic data reveals the impact of structural variants on gene regulation in the human brain. Nat Neurosci. 2022 Apr;25(4):504–14.
60. Li X, Kim Y, Tsang EK, Davis JR, Damani FN, Chiang C, et al. The impact of rare variation on gene expression across tissues. Nature. 2017 Oct;550(7675):239–43.
61. Jiang S. Tet2 at the interface between cancer and immunity. Commun Biol. 2020 Nov 12;3(1):1–6.
62. Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia. 2012 May;26(5):934–42.
63. TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia | PNAS [Internet]. [cited 2023 May 17]. Available from: https://www.pnas.org/doi/10.1073/pnas.2110758118
64. Feng Y, Li X, Cassady K, Zou Z, Zhang X. TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair. Front Oncol [Internet]. 2019 [cited 2023 May 17];9. Available from: https://www.frontiersin.org/articles/10.3389/fonc.2019.00210
65. Zeisig BB, Kulasekararaj AG, Mufti GJ, Eric So CW. SnapShot: Acute Myeloid Leukemia. Cancer Cell. 2012 Nov;22(5):698-698.e1.
66. Di Fiore R, D'Anneo A, Tesoriere G, Vento R. RB1 in cancer: Different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis: RB1/pRb INACTIVATION IN CANCER. J Cell Physiol. 2013 Aug;228(8):1676–87.

67. Cheng J, Nguyen TYD, Cygan KJ, Çelik MH, Fairbrother WG, Avsec žiga, et al. MMSplice: modular modeling improves the predictions of genetic variant effects on splicing. Genome Biol. 2019 Mar 1;20(1):48.
68. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, et al. Predicting Splicing from Primary Sequence with Deep Learning. Cell. 2019 Jan 24;176(3):535-548.e24.
69. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010 Jan;463(7277):88–92.
70. Sakatani A, Igawa T, Okatani T, Fujihara M, Asaoku H, Sato Y, et al. Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma. J Clin Exp Hematop. 2020;60(3):78–86.
71. Lenk L, Carlet M, Vogiatzi F, Spory L, Winterberg D, Cousins A, et al. CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia. Commun Biol. 2021 Jan 15;4(1):1–6.
72. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008.
73. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 1;125(9):1367–76.
74. Falini B, Martelli MP, Tiacci E. BRAF V600E mutation in hairy cell leukemia: from bench to bedside. Blood. 2016 Oct 13;128(15):1918–27.
75. Mullighan CG. Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia. Haematologica. 2009 Oct;94(10):1338–40.
76. Van Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 2010

Apr;42(4):338–42.

77. Sakai S, Nakaseko C, Takeuchi M, Ohwada C, Shimizu N, Tsukamoto S, et al. Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias. Clin Chim Acta. 2012 Oct 9;413(19):1542–8.
78. Peramangalam PS, Surapally S, Zheng S, Burns R, Zhu N, Rao S, et al. MYCN Regulates Cell Survival Via EIF4G1 in Inv(16) Acute Myeloid Leukemia. Blood. 2022 Nov 15;140(Supplement 1):9117–8.
79. Chen X, Chen X, Huang Y, Lin J, Wu Y, Chen Y. TCP1 increases drug resistance in acute myeloid leukemia by suppressing autophagy via activating AKT/mTOR signaling. Cell Death Dis. 2021 Nov 8;12(11):1058.
80. Kahle JJ, Souroullas GP, Yu P, Zohren F, Lee Y, Shaw CA, et al. Ataxin1L Is a Regulator of HSC Function Highlighting the Utility of Cross-Tissue Comparisons for Gene Discovery. PLOS Genet. 2013 Mar 28;9(3):e1003359.
81. Girardi T, Vicente C, Cools J, De Keersmaecker K. The genetics and molecular biology of T-ALL. Blood. 2017 Mar 2;129(9):1113–23.
82. Riz I, Hawley TS, Johnston H, Hawley RG. Role of TLX1 in T-cell acute lymphoblastic leukemia pathogenesis. Br J Haematol. 2009 Apr;145(1):140–3.
83. Rudat S, Pfaus A, Bühler C, Rabe S, Bullinger L, Gröschel S, et al. The RET Receptor Tyrosine Kinase Promotes Acute Myeloid Leukemia through Protection of FLT3-ITD Mutants from Autophagic Degradation. Blood. 2016 Dec 2;128(22):2849.
84. McNeer NA, Philip J, Geiger H, Ries RE, Lavallée VP, Walsh M, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. 2019 Aug;33(8):1934–43.
85. Fu JF, Shih LY, Yen TH. HOXA11 plays critical roles in disease progression and response to cytarabine in AML. Oncol Rep. 2021 Jul;46(1):150.
86. Príncipe C, Dionísio de Sousa IJ, Prazeres H, Soares P, Lima RT. LRP1B: A Giant Lost in

Cancer Translation. Pharmaceuticals. 2021 Aug 24;14(9):836.

87. Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, Ellrott K, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013 Oct;45(10):1113–20.
88. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, et al. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018 Apr 5;173(2):371-385.e18.
89. SH S, E C, NL H, ES J, SA P, H S, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues [Internet]. [cited 2023 Jun 26]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017
90. Strickland DK, Gonias SL, Argraves WS. Diverse roles for the LDL receptor family. Trends Endocrinol Metab. 2002 Mar 1;13(2):66–74.
91. May P, Woldt E, Matz RL, Boucher P. The LDL receptor‐related protein (LRP) family: An old family of proteins with new physiological functions. Ann Med. 2007 Jan 1;39(3):219–28.
92. Dieckmann M, Dietrich MF, Herz J. Lipoprotein receptors – an evolutionarily ancient multifunctional receptor family. 2010 Nov 1;391(11):1341–63.
93. Beer AG, Zenzmaier C, Schreinlechner M, Haas J, Dietrich MF, Herz J, et al. Expression of a recombinant full-length LRP1B receptor in human non-small cell lung cancer cells confirms the postulated growth-suppressing function of this large LDL receptor family member. Oncotarget. 2016 Sep 8;7(42):68721–33.
94. Haas J, Beer AG, Widschwendter P, Oberdanner J, Salzmann K, Sarg B, et al. LRP1b shows restricted expression in human tissues and binds to several extracellular ligands, including fibrinogen and apoE – carrying lipoproteins. Atherosclerosis. 2011 Jun 1;216(2):342–7.
95. Liu CX, Ranganathan S, Robinson S, Strickland DK. γ-Secretase-mediated Release of the Low Density Lipoprotein Receptor-related Protein 1B Intracellular Domain Suppresses

Anchorage-independent Growth of Neuroglioma Cells*. J Biol Chem. 2007 Mar 9;282(10):7504–11.

96. Brown LC, Tucker MD, Sedhom R, Schwartz EB, Zhu J, Kao C, et al. LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. J Immunother Cancer. 2021 Mar 1;9(3):e001792.
97. Cowin PA, George J, Fereday S, Loehrer E, Van Loo P, Cullinane C, et al. LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. Cancer Res. 2012 Aug 14;72(16):4060–73.
98. Liu F, Hou W, Liang J, Zhu L, Luo C. LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma. J Cancer. 2021 May 13;12(13):4039–48.
99. Falini B, Brunetti L, Sportoletti P, Martelli MP. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood. 2020 Oct 8;136(15):1707–21.